Enliven Therapeutics Inc [ELVN] stock prices are down -2.21% to $20.82 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ELVN shares have gain 6.17% over the last week, with a monthly amount glided 4.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enliven Therapeutics Inc [NASDAQ: ELVN] stock has seen the most recent analyst activity on June 16, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $37. Previously, BTIG Research started tracking the stock with Buy rating on December 13, 2024, and set its price target to $42. On September 09, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $37 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $32 on June 11, 2024. Mizuho initiated its recommendation with a Buy and recommended $34 as its price target on April 09, 2024. Jefferies started tracking with a Buy rating for this stock on March 29, 2023, and assigned it a price target of $27.
The stock price of Enliven Therapeutics Inc [ELVN] has been fluctuating between $13.30 and $30.03 over the past year. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. Enliven Therapeutics Inc [NASDAQ: ELVN] shares were valued at $20.82 at the most recent close of the market. An investor can expect a potential return of 149.76% based on the average ELVN price forecast.
Analyzing the ELVN fundamentals
Gross Profit Margin for this corporation currently stands at -0.24% with Operating Profit Margin at -361.52%, Pretax Profit Margin comes in at -317.14%, and Net Profit Margin reading is -317.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.29 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Enliven Therapeutics Inc [NASDAQ:ELVN]’s Current Ratio is 32.58. Also, the Quick Ratio is 32.58, while the Cash Ratio stands at 7.85.
Transactions by insiders
Recent insider trading involved Patel Anish, CHIEF OPERATING OFFICER, that happened on Oct 07 ’25 when 6667.0 shares were sold. CHIEF FINANCIAL OFFICER, Hohl Benjamin completed a deal on Sep 29 ’25 to sell 3250.0 shares. Meanwhile, CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold 4000.0 shares on Sep 26 ’25.
